260
Participants
Start Date
May 18, 2023
Primary Completion Date
September 25, 2024
Study Completion Date
September 25, 2024
Difelikefalin Injection
Participants receive Difelikefalin three times a week (0.5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Placebo Injection
Participants receive Placebo three times a week (0.5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Investigator Site 25, Baotou
Investigator Site 01, Beijing
Investigator Site 07, Beijing
Investigator Site 26, Changsha
Investigator Site 06, Guangzhou
Investigator Site 12, Jiaxing
Investigator Site 02, Lanzhou
Investigator Site 34, Mianyang
Investigator Site 03, Nanjing
Investigator Site 10, Nanjing
Investigator Site 19, Nanjing
Investigator Site 36, Nantong
Investigator Site 40, Shanghai
Investigator Site 18, Shenyang
Investigator Site 21, Shenyang
Investigator Site 16, Shenzhen
Investigator Site 08, Shihezi
Investigator Site 32, Shijiazhuang
Investigator Site 41, Shijiazhuang
Investigator Site 20, Taiyuan
Investigator Site 24, Taiyuan
Investigator Site 39, Tianjin
Investigator Site 04, Ürümqi
Investigator Site 17, Wuhan
Investigator Site 33, Wuxi
Investigator Site 13, Xiamen
Investigator Site 15, Xianyang
Investigator Site 22, Xining
Investigator Site 38, Xinxiang
Investigator Site 11, Yangzhou
Investigator Site 30, Yibin
Investigator Site 29, Yinchuan
Investigator Site 23, Zhengzhou
Investigator Site 31, Zhenjiang
Investigator Site 35, Zhuzhou
Tigermed Consulting Co., Ltd
INDUSTRY
Vifor Fresenius Medical Care Renal Pharma
INDUSTRY